Clinical Trials Arena April 24, 2024
The biopharma industry should be proactive in its approach to changing requirements for diversity in clinical trial populations.
Representatives from the biopharma industry agreed that “intentional effort” is required from sponsors to ensure diverse populations are reached in clinical trials for cancer treatments.
The remarks were made from a panel at the Clinical Trials In Oncology West Coast 2024 in San Francisco held from 23 April to 24 April.
“The entire system of clinical development is biased [in terms of patient diversity]. It’s difficult to change that dynamic, but it is happening slowly,” said Oscar Segurado, ASC Therapeutics’ chief medical officer.
“Ultimately when a drug is approved, we want the drug to have the biggest number of patients available to...
Today's Sponsors
Today's Sponsor